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Abstract
Background: Manganese based agents are intracellular and accumulate inside myocytes allowing for different
imaging strategies compared to gadolinium contrasts. While previous agents release manganese very slowly in the
circulation, MnCl2 allows for rapid Mn2
+ uptake in myocytes, creating a memory effect that can be potentially
explored. Data on animal models are very encouraging but the safety and efficacy of this approach in humans has
not yet been investigated. Therefore, our objectives were to study the safety and efficacy of a rapid infusion of
manganese chloride (MnCl2) for cardiovascular magnetic resonance (CMR) in humans.
Methods: Fifteen healthy volunteers underwent a CMR scan on a 1.5 T scanner. Before the infusion, cardiac
function was calculated and images of a short axis mid-ventricular slice were obtained using a 2D and 3D
gradient-echo inversion recovery (GRE-IR) sequence, a phase-sensitive IR sequence and a single breath-hold
segmented IR prepared steady-state precession acquisition for T1 calculations. MnCl2 was infused over three
minutes at a total dose of 5 μMol/kg. Immediately after the infusion, and at 15 and 30 minutes later, new images
were obtained and cardiac function re-evaluated.
Results: There was a significant decrease in T1 values compared to baseline, sustained up to 30 minutes after the
MnCl2 infusion (pre,839 ± 281 ms; 0 min, 684 ± 99; 15 min, 714 ± 168; 30 min, 706 ± 172, P = 0.003). The 2D and
3D GRE-IR sequence showed the greatest increase in signal-to-noise ratio compared to the other sequences
(baseline 6.6 ± 4.2 and 9.7 ± 5.3; 0 min, 11.3 ± 4.1 and 15.0 ± 8.7; 15 min, 10.8 ± 4.0 and 16.9 ± 10.2; 30 min,
10.6 ± 5.2 and 16.5 ± 8.3, P < 0.001 for both). There was a slight increase in systolic pressure and heart rate after
three and four minutes of the infusion with normalization of these parameters thereafter. Patients showed good
tolerance to MnCl2 with no major adverse events, despite all reporting transient facial flush.
Conclusions: In the short term, MnCl2 appears safe for human use. It effectively decreases myocardium T1,
maintaining this effect for a relatively long period of time and allowing for the development of new imaging
strategies in CMR, especially in ischemia research.
Background
Cardiovascular magnetic resonance (CMR) has become
one of the most important diagnostic tools in cardiology,
especially in infarct detection and myocardial perfusion
in coronary artery disease [1,2]. Gadolinium contrast
enhanced CMR is frequently used for that purpose with a
relatively good safety profile but has been recently asso-
ciated with systemic nephrogenic fibrosis [3]. Moreover,
due to their extracellular distribution, gadolinium che-
lates are rapidly washed out of myocardial tissue, limiting
the spatial and temporal resolution as well as the volume
coverage that can be obtained in CMR studies [4]. Intra-
cellular paramagnetic agents that are retained inside
myocytes for longer periods may circumvent these limita-
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In solution, MnCl2 freely dissociates into Mn2+ and Cl-
ions. The manganese ions, which are strongly paramag-
netic, behave in vivo as a calcium analogue, and actively
enter myocytes through voltage-gated calcium channels
[5,6]. Once inside myocytes, manganese is retained
within intracellular organelles such as mitochondria,
remaining in the cell for several days. In animals, experi-
mental studies showed that the use of MnCl2 allows for
the detection of ischemic tissues as well as infarcted
areas with great accuracy [7-9]. However, due to compe-
tition with calcium for voltage-gated channels there has
always been a safety concern regarding the use of manga-
nese in high concentrations because of the possibility of
acute heart failure or even cardio-pulmonary arrest [10].
Despite animal studies having shown that this concern
does exist in extremely high doses, at lower concentra-
tions MnCl2 has not been associated with any serious
adverse short term events [11]. The use other manganese
compounds like manganese dipyridoxyl-diphosphate
(MnDPDP) has been done in humans before with a good
safety profile [12]. However, because MnCl2 releases
Mn2+ much more rapidly than MnDPDP allowing for
more rapid uptake of the free manganese ions by myo-
cytes, it may in one hand promote deleterious effects on
heart function due to direct competition with Ca2+ with
possible decrease in inotropism [13] at the same time
providing for potential advantages in cardiac imaging
techniques due to its long lasting intracellular properties.
Based on these observations, the purpose of this study
was to investigate the safety and efficacy of a rapid infu-
sion of MnCl2 for CMR in humans. We found that low-
dose MnCl2 appears to offer a safe profile with signifi-




Fifteen healthy volunteers of both sexes with ages from
18 to 60 were prospectively selected for the study. Inclu-
sion criteria consisted of absence of previous cardiovas-
cular disease or risk factors (hypertension, dyslipidemia,
diabetes, acute myocardial infarction, angina pectoris,
valvular disease) and normal left ventricular function
(normal chest radiograph or echocardiography with an
ejection fraction > 0.60 without symptoms of heart fail-
ure). We excluded from the study individuals taking any
chronic medication, current smokers, and those with a
history of liver diseases, arrhythmias detected in a rest-
ing electrocardiogram (ECG) or with known absolute
contra-indications for undergoing a CMR study.
Study Protocol
After the initial ECG to assess PR, QRS and QT inter-
vals, subjects underwent a CMR exam without any
contrast in a 1.5 T scanner (Siemens Symphony,
Erlangen, Germany) with a four-element phased-array
coil. After localizer sequences, cine images for ventricu-
lar function evaluation were obtained using previously
described steady-state free-precession (SSFP) sequences
in short axis, two-chamber and four-chamber views.
After that, a short axis mid-ventricular slice was chosen
and four different imaging protocols acquired: (1) 2D
gradient-echo inversion recovery (GRE-IR) sequence
(TR 6.0 ms; TE 4.18 ms; matrix 256 × 128; FOV 350 ×
260; resolution 1.37 × 2.0 × 8 mm; FA 25°; BW 130 Hz/
px; TI 400 ms; 25 segments; 2 RR intervals); (2) 3D
GRE-IR sequence (TR 3.8 ms; TE 1.55 ms; matrix 256 ×
102; FOV 350 × 260; resolution 1.37 × 2.55 × 5 mm; FA
10°; BW 360 Hz/px; TI 400 ms; 51 segments; 1 RR
interval); (3) phase-sensitive IR sequence (same para-
meters as the 2D GRE-IR) and (4) a single breath-hold
segmented IR prepared steady-state precession (sIR-
SSFP) acquisition for T1 calculations (TR 26.7 ms; TE
1.27 ms; matrix 192 × 72; FOV 350 × 260; resolution
1.82 × 3.61 × 8 mm; FA 50°; BW 965 Hz/px; TI variable;
9 segments; 2 RR intervals).
After acquiring these images, subjects were removed
from inside the magnet without moving from the table.
Venous access was obtained and 5 μMol/kg of MnCl2 was
manually infused over three minutes (1.67 μMol/kg/min).
MnCl2 was manufactured in 10 ml vials of 20 mg/mL
(Farmacia do Hospital das Clinicas da USP, Sao Paulo,
Brazil) and the total amount of MnCl2 per subject was cal-
culated, drawn from the vial and diluted to 10 mL with
normal saline. During and ten minutes after the infusion,
heart rate, arterial pressure and any arrhythmias were
recorded (Maglife C Plus, Schiller Medical, Switzerland).
Subjects were questioned regarding symptoms throughout
the study.
Immediately after the infusion, subjects entered the
scanner once again and the same single slice images were
obtained using the four previously described sequences
with cine images being acquired shortly after that. At fif-
teen and thirty minutes after the end of the infusion, new
single slice images were again obtained as described, with
new cine images at thirty minutes only. At the end of the
study, a final ECG was performed before the subject left
the facility. After six months, all subjects were contacted
by telephone and questioned about the occurrence of
clinical events that included: death by any cause, myocar-
dial infarction, angina symptoms (mainly typical chest
pain), heart failure symptoms (dyspnea, lower limb
edema, fatigue) and neurological disturbances (gait
changes, tremors, motor and sensitive deficits).
Ethical Issues
The local institutional review board approved the study
methods and all subjects provided written informed
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consent. Since this was the first reported use of MnCl2
in humans, great care was taken to assure safety and
ethical considerations in applying the drug. The local
ethics committee required that the lowest dose of the
drug was to be used (5 μMol/kg) since this concentra-
tion of manganese had already been used in humans
with the commercially approved contrast MnDPDP.
This dose along was chosen along with an infusion rate
significantly lower than the reported doses shown to
cause any adverse effects on heart function in animals.
The ethics committee therefore understood that this
new agent would provide a total dose of manganese
similar to the one approved for MnDPDP while releas-
ing Mn2+ more rapidly but well below a perilous rate as
previously described. Finally, patients were closely moni-
tored before, during and after the infusions and stayed
in the lab for two hours after the procedure. We also
took the care of contacting each individual six months
after the infusion to assess any potential complications
not predicted in the day of the CMR study.
Image Analysis
All images were anonymized prior to analysis for subject
name and timing of the study. All images were analyzed
by the same reader (JLF, six years of experience in CMR),
in random order. The choice of a single reader for all
images was done due to the blind reading form described
for image analysis as well as for the rather objective
values obtained from this analysis, requiring very little
subjective assessment. Cine images were evaluated for
diastolic volume, systolic volume and ejection fraction
using commercial software (Argus Syngo MR2004A, Sie-
mens, Germany). Volumes were determined semi-auto-
matically by drawing endocardial borders in each slice at
systole and diastole from base to apex excluding papillary
muscles according to established references [14]. For sig-
nal intensity changes before and at different time points
after infusion of MnCl2, a manual region of interest
(ROI) was drawn including all the myocardium for each
of the pulse sequences and the mean signal intensity was
chosen for each ROI. Signal to noise ratio (SNR) was cal-
culated as the ratio between the ROI mean and the stan-
dard deviation of background noise. Contrast to noise
ratio (CNR) was calculated as the difference between pre-
contrast SNRs and each postcontrast values [15]. To cal-
culate T1 and R1 (1/T1), we used the data from the sIR-
SSFP sequence with multiple inversion times, fitting the
curve using customized programs written in Matlab
(Mathworks Inc, USA) according to previously published
methods [16].
Statistical Analysis
Sample size calculation was not performed previous to
the study; rather, the number of subjects was selected
according to other similar studies with MnCl2 in
animals which used from eight to thirty subjects
[7,17,18]. We compared CNR and SNR data, T1 and R1
values, heart rate, arterial pressure, ventricular function
data and ECG parameters using analysis of variance for
repeated measures with Statview 5.0 (SAS Institute,
USA) with LSD post-hoc test as needed. A value of P <
0.05 was considered statistically significant.
Results
All the 15 subjects selected (age 46 ± 11 years, five men)
completed the study. No subject suffered any major
adverse effect during the CMR exam or within six
months of completing the study.
Efficacy
After MnCl2 infusion there was a significant increase in
mean SNR in all sequences analyzed except in the sIR-
SSFP sequence (Table 1). Myocardium T1 values also
decreased significantly immediately after the infusion,
maintaining this effect almost uniformly throughout
thirty minutes.
To evaluate if the changes observed stayed up to
30 minutes after the infusion in the different sequences
used and if signal intensity increase differed among them,
we compared CNR values for each sequence in different
time points (Figure 1). No significant differences were
found among each time point supporting the findings of
the T1 values that the increase in signal persists for up to
30 minutes after infusion (P = 0.52). Regarding the com-
parison among the different sequences, we found that
GRE-IR 2D and GRE-IR 3D demonstrated significant
increases in CNR compared to IR-SSFP (P = 0.015 and
P = 0.03 respectively) and phase sensitive IR (P = 0.008
and P = 0.017 respectively) almost doubling the baseline
SNR values. While phase sensitive IR also showed a
significant increase in SNR compared to baseline this
increase was not as prominent as the observed with the
GRE-IR sequences. An example of images at all
time points with the GRE-IR 2D sequence is shown in
Figure 2. An example of images pre and 30 minutes after
infusion of MnCl2 with the other sequences are shown in
Figure 3.
Short Term Safety
A small but significant transient increase in arterial
systolic and diastolic pressure was observed after the
infusion of MnCl2, with maintenance of this effect up to
four minutes after the drug was injected (Figure 4). At
ten minutes, both pressures had returned to baseline
values. While significant, blood pressure values kept
within the normal range during the whole study. The
heart rate also showed a small but significant elevation
from 74.1 ± 10 beats per minute at baseline to a
Fernandes et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:6
http://www.jcmr-online.com/content/13/1/6
Page 3 of 9
maximum of 80.2 ± 9.8 at the end of the infusion (P =
0.002). Changes in heart rate were already observed
after two minutes of the infusion and disappeared at ten
minutes after drug injection was completed. Pre infusion
ECG showed a PR and QRS duration of 139.2 ± 15.0
and 80.5 ± 19.3 msec respectively without any signifi-
cant differences compared to post infusion ECG of
141.2 ± 16.5 and 78.9 ± 22.2 (P = 0.99 and 0.55 respec-
tively). Corrected QT duration was also not changed
comparing pre and post measures (398.8 ± 26.7 versus
405.5 ± 29.3, P = 0.39).
One of the main concerns regarding the use of MnCl2
in humans was a significant change in ventricular func-
tion due to competition of manganese with calcium for
entering myocytes. This was not seen with this dose and
speed of infusion of MnCl2 (table 2). No significant dif-
ferences were observed after the infusion of the drug or
after thirty minutes regarding left ventricular ejection
fraction, diastolic and systolic volumes.
Finally, subjects did not report experiencing any ser-
ious adverse symptoms during or after the infusion of
MnCl2, demonstrating good tolerance for the drug.
However, after two minutes of infusion, all subjects
reported feeling a transient facial flush that lasted up to
two minutes after stopping the infusion. This effect did
not prevent any subject from completing the study.
On the six month follow-up, no patient reported any
pre-specified neurologic or cardiologic adverse event or
symptom.
Discussion
Manganese has been described in the past as a promising
paramagnetic contrast agent and was tested in parallel to
gadolinium [13]. When administered in an unchelated
form, such as MnCl2, manganese has a short plasma half-
life with 99% of free Mn2+ being cleared from plasma
within 2.7 minutes [19]. Its distribution is almost entirely
intracellular, where it is retained mainly within mitochon-
dria with very slow recirculation [20]. This property was
previously observed in animal models where changes T1
lasted up to 2 hours after infusion of the drug [7]. In our
study, we tested this effect in humans and similar results
were found with a significant decrease in longitudinal
relaxation, which lasted at least thirty minutes after the
infusion. In our view, this first human experiment with the
drug opens many opportunities to further explore myocar-
dium perfusion uptake and calcium activity under various
physiological and pathological conditions, although further
optimization of sequence protocols will be needed to dif-
ferentiate tissue with varying degrees of manganese
uptake. Differences between normal and ischemic myocar-
dial tissue have been identified in dogs previously [18] and
this approach might be reproducible in humans if the
decrease in T1 values observed are large enough with the
dose used in the study, allowing for possible infusion of
MnCl2 outside the magnet and acquisition of images at
rest under steady state conditions using higher resolution
sequences, similar to a nuclear thallium test [21].
However, to be useful for human studies, it is mandatory
that safety issues are taken into account since previous
animal studies have shown that in very large doses
Figure 1 Contrast to noise (CNR) values at different time points
after the infusion of MnCl2 using different sequences. Both 2D
and 3D gradient-echo inversion recovery (GRE-IR) sequences showed
the greatest increase in CNR compared to baseline than Phase contrast
inversion recovery (IR) and IR steady state free precession (SSFP). There
were no significant CNR differences among each sequence
immediately, at 15 or 30 minutes after the infusion of MnCl2.
Table 1 Signal to noise ratio and T1/R1 values at baseline, immediately, 15 and 30 minutes after the infusion of MnCl2
using different sequences.
Variable Pre 0 min 15 min 30 min P
GRE-IR 2D 6.6 ± 4.2 11.3 ± 4.1 10.8 ± 4.0 10.6 ± 5.2 < 0.0001
GRE-IR 3D 9.7 ± 5.3 15.0 ± 8.7 16.9 ± 10.2 16.5 ± 8.3 < 0.001
IR-SSFP 10.7 ± 4.2 12.8 ± 4.2 11.5 ± 2.4 12.7 ± 2.5 0.16
Phase Sensitive IR 13.5 ± 3.0 16.3 ± 3.9 15.9 ± 4.2 14.6 ± 3.6 0.02
T1 (ms) 839 ± 281 684 ± 99 714 ± 168 706 ± 172 0.003
R1 (Hz) 1.32 ± 0.46 1.50 ± 0.24 1.47 ± 0.34 1.50 ± 0.39 0.02
GRE-IR = gradient-echo inversion recovery; SSFP = steady-state free precession.
Data represents mean ± SD.
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manganese can induce acute heart failure [22]. In our
study, we chose the total dose of 5 μMol/kg of MnCl2
with an infusion rate of 1.67 μMol/kg/min. Animal studies
have used variable doses from 1 to 420 μMol/kg (with
most studies limiting the dose from 5 to 30 μMol/kg) [23]
with infusion rates of most commonly within the range of
1 to 15 μMol/kg/min [17,18,24,25]. Only studies with very
high infusion rates (generally over 100 μMol/kg/min) have
shown serious adverse effects in heart rate or arterial pres-
sure [11]. In our study, blood pressure did not change sig-
nificantly during the infusion of manganese with a slight
increase in heart rate possibly compensating any negative
inotropic provoked by the ion. The apparent discrepancy
with previous data might be related to the differences in
doses used since in this study a lower dose of MnCl2 was
infused. In that regard, the infusion rate of MnCl2 seems
to be much more important regarding acute safety than
the total dose used since free manganese directly competes
with calcium for voltage channels in the heart. At the
same time, if one wants to look at uptake by myocytes
during ischemia (for example, at the peak of a treadmill
test), it is important to guarantee a very fast delivery of
Figure 2 Signal changes in a typical subject using the 2D gradient-echo inversion recovery 2D sequence: (A) pre contrast image; (B)
immediately after the infusion; (C) 15 minutes after; (D) 30 minutes after.
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Mn2+ to the heart. Having that in mind, our data suggests
that the infusion rate observed in our study guarantees a
short term safety profile without significant clinical
changes in heart rate, arterial pressure and ventricular
function in patients without heart disease, while still per-
mitting delivery of MnCl2 at a rate where possible
ischemia detection might prove achievable. Whether
higher infusion rates or total doses of the drug might exhi-
bit the same safety profile with better efficacy remains to
be shown.
The only other manganese based contrast agent to have
been used in humans previously for the study of the heart
Figure 3 Signal changes pre and 30 minutes after the infusion of MnCl2 using different sequences in three different patients: (A) and
(B) gradient-echo inversion recovery 3D; (C) and (D) Phase contrast inversion recovery; (E) and (F) steady state free precession.
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is MnDPDP, which is a chelated agent, and has different
pharmacokinetics and biological distribution from MnCl2
[26-30]. With MnDPDP using similar concentrations of
manganese as our study, the authors demonstrated a R1
increase of 0.38 ± 0.03 seconds in non-infarcted areas at
one hour, higher than our finding of 0.26 ± 0.06 seconds
at thirty minutes. This might have been achieved by dif-
ferent properties of MnDPDP to release free manganese
or recirculation of Mn2+. Despite that, the delivery of
Mn2+ to myocytes using MnDPDP is very slow while
MnCl2 promotes rapid availability of the ion, a potential
advantage especially for stress ischemia studies. Never-
theless, if MnCl2 is to be used in humans over the estab-
lished MnDPDP remains to be proven in a larger study
in patients with ischemic heart disease. The other manga-
nese compound used in humans was EVP 1001-1, a com-
pound with a short vascular half-life of 1.5 minutes with
flow-dependent differences in uptake similar to the uses
proposed for MnCl2 [26,27]. This compound is being
tested in a Phase II human trial without any results
reported yet (NCT00340925) and might provide some of
the advantages observed with MnCl2 with an adequate
safety profile as well.
Limitations on safety assessment
This study has many safety limitations and these have to
be taken into account when interpreting our data. First,
the main objective of this study was to assess the acute
effects of free Mn2+ to the heart. Therefore, we did not
evaluate other possible effects of MnCl2 on the liver or
kidneys, did not measure the concentration of the ion in
the blood or urine or its interaction with iron or copper
metabolism. While we did make contact with the sub-
jects six months after the exam regarding clinical conse-
quences of manganese toxicity on other organs, the
number of subjects studied and the period of observa-
tion do not allow us to reach any conclusions regarding
long-term safety. A publication studying methcathinone
users with high levels of whole blood manganese has
shown that the mean time between extrapyramidal
symptoms (a known effect of chronic manganese intoxi-
cation [31]) and drug use was 5.8 years [32]. There are
rare descriptions of acute intoxication by manganese
despite its frequent use in industry with most of the
cases being described after long years of chronic expo-
sure to the substance [33,34]. Nevertheless, this issue
was not addressed in our study.
Another limitation of this study is that we only looked
at normal individuals without left ventricular dysfunc-
tion or ischemic heart disease. It is not known if the
safety and efficacy data presented here can be repro-
duced in patients who already have borderline cardiac
function or previous ischemia. While the main cardio-
toxicity of manganese is related more to the extracellu-
lar than the intracellular concentration of Mn2+ [35] the
possibility of evaluating cardiac function at a later time
would have been wise.
Finally, this preliminary data might be considered lim-
ited to further advance the use of substance in humans,
especially in some countries where other safety mea-
sures would be required to allow for subsequent trials
with MnCl2.
The study was limited to a fixed infusion rate and
total amount of MnCl2, preventing us from addressing
whether higher doses would be tolerated, more efficient
or even allowing for the study of concentration and sig-
nal enhancement relationships. Nevertheless, it had been
shown with MnDPDP that increasing the dose to 10 or
15 μMol/kg did not yield further myocardial enhance-
ment thus only allowing for an increase in side effects
[30]. Finally, while we could also have obtained more
delayed (> 30 min) imaging points, we thought that this
would deviate from the potential clinical applications
suggested by the agent as well as not be practical in
routine human scans or useful for assessment of safety
issues.
Conclusions
In conclusion, our data suggests that low-dose MnCl2
(5 μMol/kg) has a good short-term cardiac safety profile in
humans promoting a significant decrease in myocardium
Figure 4 Arterial blood pressure and heart rate variations
during and after the infusion of MnCl2. * P < 0.05 compared to
pre infusion values.
Table 2 Changes in ejection fraction and cardiac volumes
compared to baseline immediately, 15 and 30 minutes
after MnCl2 infusion
Variable Pre 0 min 30 min P
Ejection Fraction (%) 65.7 ± 1.7 67.1 ± 1.6 67.0 ± 1.9 0.22
Systolic volume (mL) 39.8 ± 4.3 38.3 ± 3.6 37.1 ± 4.1 0.24
Diastolic Volume (mL) 114.0 ± 8.4 120 ± 11.2 110.0 ± 8.3 0.12
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T1 for a relatively long time. From this data, we believe
that new strategies to study coronary heart disease with
CMR can be designed with special focus on ischemia with
higher resolution sequences and out of the magnet proto-
cols, taking advantage of the longer-lasting changes in
relaxation times produced by the agent.
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